Hypercholesterolemia in non-insulin-dependent diabetes mellitus

different effect of simvastatin on VLDL and LDL cholesterol levels

M. Cassader, G. Ruiu, R. Gambino, N. Alemanno, F. Veglia, G. Pagano

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Non-insulin-dependent diabetes mellitus (NIDDM) is often characterized by an increase in VLDLtriglyceride, VLDL-cholesterol, LDL-cholesterol and a reduction in HDL-cholesterol. HMG-CoA reductase inhibitors significantly lower cholesterol rates and have an indirect effect on the LDL receptor. We measured the effect of simvastatin in 28 hypercholesterolemic subjects, including 14 with NIDDM in good metabolic control (HbAIc 7.8% ± 1.3%). A 24-week treatment with 10 mg/day (weeks 1-4), 20 mg/day (weeks 5-8) and 40 mg/day (weeks 9-24) simvastatin revealed different responses in diabetic and non-diabetic patients. Total cholesterol, LDL-cholesterol and apo B decreased significantly in both groups (less in the diabetics), whereas only NIDDM patients displayed a significant reduction in VLDL-cholesterol and VLDL-apo B. In the non-diabetics, the reduction in plasma cholesterol was mainly confined to the LDL fraction (276 ± 65 vs. 132 ± 28 mg/dl), whereas a significant fall in VLDL-cholesterol (45 ± 19 vs. 21 ± 10 mg/dl) was more evident in the NIDDM patients. Simvastatin also influenced plasma apo B levels (221 ± 33 vs 134 ± 23 mg/dl in non-diabetics and 182 ± 44 vs. 134 ± 30 mg/dl in diabetics). Significant reduction of apo B, LDL-apo B (205 ± 39 vs. 128 ± 23 mg/dl) in the non-diabetics and VLDL-apo B (16 ± 5 vs. 9 ± 2 mg/dl) in the diabetics, indicates that the VLDL are primarily concerned when statins are administered in NIDDM. Our data suggest that statins are also useful in the treatment of hypercholesterolernia in NIDDM to prevent the macroangiopathic complications often observed in this disease.

Original languageEnglish
Pages (from-to)47-53
Number of pages7
JournalAtherosclerosis
Volume99
Issue number1
DOIs
Publication statusPublished - 1993

Fingerprint

VLDL Cholesterol
Simvastatin
Apolipoproteins B
Hypercholesterolemia
LDL Cholesterol
Type 2 Diabetes Mellitus
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Cholesterol
LDL Receptors
HDL Cholesterol
Therapeutics

Keywords

  • Hypercholesterolemia
  • Non-insulin-dependent diabetes mellitus
  • Simvastatin

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Hypercholesterolemia in non-insulin-dependent diabetes mellitus : different effect of simvastatin on VLDL and LDL cholesterol levels. / Cassader, M.; Ruiu, G.; Gambino, R.; Alemanno, N.; Veglia, F.; Pagano, G.

In: Atherosclerosis, Vol. 99, No. 1, 1993, p. 47-53.

Research output: Contribution to journalArticle

Cassader, M. ; Ruiu, G. ; Gambino, R. ; Alemanno, N. ; Veglia, F. ; Pagano, G. / Hypercholesterolemia in non-insulin-dependent diabetes mellitus : different effect of simvastatin on VLDL and LDL cholesterol levels. In: Atherosclerosis. 1993 ; Vol. 99, No. 1. pp. 47-53.
@article{96816a33b1ad43f5a5b482dbfcba5f47,
title = "Hypercholesterolemia in non-insulin-dependent diabetes mellitus: different effect of simvastatin on VLDL and LDL cholesterol levels",
abstract = "Non-insulin-dependent diabetes mellitus (NIDDM) is often characterized by an increase in VLDLtriglyceride, VLDL-cholesterol, LDL-cholesterol and a reduction in HDL-cholesterol. HMG-CoA reductase inhibitors significantly lower cholesterol rates and have an indirect effect on the LDL receptor. We measured the effect of simvastatin in 28 hypercholesterolemic subjects, including 14 with NIDDM in good metabolic control (HbAIc 7.8{\%} ± 1.3{\%}). A 24-week treatment with 10 mg/day (weeks 1-4), 20 mg/day (weeks 5-8) and 40 mg/day (weeks 9-24) simvastatin revealed different responses in diabetic and non-diabetic patients. Total cholesterol, LDL-cholesterol and apo B decreased significantly in both groups (less in the diabetics), whereas only NIDDM patients displayed a significant reduction in VLDL-cholesterol and VLDL-apo B. In the non-diabetics, the reduction in plasma cholesterol was mainly confined to the LDL fraction (276 ± 65 vs. 132 ± 28 mg/dl), whereas a significant fall in VLDL-cholesterol (45 ± 19 vs. 21 ± 10 mg/dl) was more evident in the NIDDM patients. Simvastatin also influenced plasma apo B levels (221 ± 33 vs 134 ± 23 mg/dl in non-diabetics and 182 ± 44 vs. 134 ± 30 mg/dl in diabetics). Significant reduction of apo B, LDL-apo B (205 ± 39 vs. 128 ± 23 mg/dl) in the non-diabetics and VLDL-apo B (16 ± 5 vs. 9 ± 2 mg/dl) in the diabetics, indicates that the VLDL are primarily concerned when statins are administered in NIDDM. Our data suggest that statins are also useful in the treatment of hypercholesterolernia in NIDDM to prevent the macroangiopathic complications often observed in this disease.",
keywords = "Hypercholesterolemia, Non-insulin-dependent diabetes mellitus, Simvastatin",
author = "M. Cassader and G. Ruiu and R. Gambino and N. Alemanno and F. Veglia and G. Pagano",
year = "1993",
doi = "10.1016/0021-9150(93)90049-Z",
language = "English",
volume = "99",
pages = "47--53",
journal = "Atherosclerosis",
issn = "0021-9150",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - Hypercholesterolemia in non-insulin-dependent diabetes mellitus

T2 - different effect of simvastatin on VLDL and LDL cholesterol levels

AU - Cassader, M.

AU - Ruiu, G.

AU - Gambino, R.

AU - Alemanno, N.

AU - Veglia, F.

AU - Pagano, G.

PY - 1993

Y1 - 1993

N2 - Non-insulin-dependent diabetes mellitus (NIDDM) is often characterized by an increase in VLDLtriglyceride, VLDL-cholesterol, LDL-cholesterol and a reduction in HDL-cholesterol. HMG-CoA reductase inhibitors significantly lower cholesterol rates and have an indirect effect on the LDL receptor. We measured the effect of simvastatin in 28 hypercholesterolemic subjects, including 14 with NIDDM in good metabolic control (HbAIc 7.8% ± 1.3%). A 24-week treatment with 10 mg/day (weeks 1-4), 20 mg/day (weeks 5-8) and 40 mg/day (weeks 9-24) simvastatin revealed different responses in diabetic and non-diabetic patients. Total cholesterol, LDL-cholesterol and apo B decreased significantly in both groups (less in the diabetics), whereas only NIDDM patients displayed a significant reduction in VLDL-cholesterol and VLDL-apo B. In the non-diabetics, the reduction in plasma cholesterol was mainly confined to the LDL fraction (276 ± 65 vs. 132 ± 28 mg/dl), whereas a significant fall in VLDL-cholesterol (45 ± 19 vs. 21 ± 10 mg/dl) was more evident in the NIDDM patients. Simvastatin also influenced plasma apo B levels (221 ± 33 vs 134 ± 23 mg/dl in non-diabetics and 182 ± 44 vs. 134 ± 30 mg/dl in diabetics). Significant reduction of apo B, LDL-apo B (205 ± 39 vs. 128 ± 23 mg/dl) in the non-diabetics and VLDL-apo B (16 ± 5 vs. 9 ± 2 mg/dl) in the diabetics, indicates that the VLDL are primarily concerned when statins are administered in NIDDM. Our data suggest that statins are also useful in the treatment of hypercholesterolernia in NIDDM to prevent the macroangiopathic complications often observed in this disease.

AB - Non-insulin-dependent diabetes mellitus (NIDDM) is often characterized by an increase in VLDLtriglyceride, VLDL-cholesterol, LDL-cholesterol and a reduction in HDL-cholesterol. HMG-CoA reductase inhibitors significantly lower cholesterol rates and have an indirect effect on the LDL receptor. We measured the effect of simvastatin in 28 hypercholesterolemic subjects, including 14 with NIDDM in good metabolic control (HbAIc 7.8% ± 1.3%). A 24-week treatment with 10 mg/day (weeks 1-4), 20 mg/day (weeks 5-8) and 40 mg/day (weeks 9-24) simvastatin revealed different responses in diabetic and non-diabetic patients. Total cholesterol, LDL-cholesterol and apo B decreased significantly in both groups (less in the diabetics), whereas only NIDDM patients displayed a significant reduction in VLDL-cholesterol and VLDL-apo B. In the non-diabetics, the reduction in plasma cholesterol was mainly confined to the LDL fraction (276 ± 65 vs. 132 ± 28 mg/dl), whereas a significant fall in VLDL-cholesterol (45 ± 19 vs. 21 ± 10 mg/dl) was more evident in the NIDDM patients. Simvastatin also influenced plasma apo B levels (221 ± 33 vs 134 ± 23 mg/dl in non-diabetics and 182 ± 44 vs. 134 ± 30 mg/dl in diabetics). Significant reduction of apo B, LDL-apo B (205 ± 39 vs. 128 ± 23 mg/dl) in the non-diabetics and VLDL-apo B (16 ± 5 vs. 9 ± 2 mg/dl) in the diabetics, indicates that the VLDL are primarily concerned when statins are administered in NIDDM. Our data suggest that statins are also useful in the treatment of hypercholesterolernia in NIDDM to prevent the macroangiopathic complications often observed in this disease.

KW - Hypercholesterolemia

KW - Non-insulin-dependent diabetes mellitus

KW - Simvastatin

UR - http://www.scopus.com/inward/record.url?scp=0027500527&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027500527&partnerID=8YFLogxK

U2 - 10.1016/0021-9150(93)90049-Z

DO - 10.1016/0021-9150(93)90049-Z

M3 - Article

VL - 99

SP - 47

EP - 53

JO - Atherosclerosis

JF - Atherosclerosis

SN - 0021-9150

IS - 1

ER -